Premium
Anticancer Therapeutics That Target Selenoenzymes: Synthesis, Characterization, in vitro Cytotoxicity, and Thioredoxin Reductase Inhibition of a Series of Gold(I) Complexes Containing Hydrophilic Phosphine Ligands
Author(s) -
Vergara Elena,
Casini Angela,
Sorrentino Francesca,
Zava Olivier,
Cerrada Elena,
Rigobello Maria Pia,
Bindoli Alberto,
Laguna Mariano,
Dyson Paul J.
Publication year - 2010
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.200900370
Subject(s) - thioredoxin reductase , chemistry , cytotoxicity , bioconjugation , phosphine , biochemistry , thioredoxin , enzyme , cisplatin , stereochemistry , in vitro , biology , genetics , catalysis , chemotherapy
Gold(I) complexes bearing water‐soluble phosphine ligands, including 1,3,5‐triaza‐7‐phosphaadamantane (PTA), 3,7‐diacetyl‐1,3,7‐triaza‐5‐phosphabicyclo[3.3.1]nonane (DAPTA), and sodium triphenylphosphine trisulfonate (TPPTS), in combination with thionate ligands, were screened for their antiproliferative activities against human ovarian cancer cell lines A2780 either sensitive or resistant to cisplatin. In addition, the compounds were screened for their inhibition of mammalian thioredoxin reductases (TrxR), enzymes that are overexpressed in many tumor cells and contribute to drug resistance. The gold(I)–phosphine complexes efficiently inhibited cytosolic and mitochondrial TrxRs at concentrations that did not affect the related oxidoreductase glutathione reductase (GR). Additional complementary information on the enzyme metallation process and potential gold binding sites was obtained through the application of a specific biochemical assay using a thiol‐tagging reagent, BIAM (biotin‐conjugated iodoacetamide).